Consensus Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
10.54 ^USD	-1.50%		-0.09%	-25.72%

Mar. 18	JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	MT
Mar. 05	Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Amicus Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

a00827.pdjp5IT8YUo4vrKN30rpolPQS-AxvnrXZACp8Lall9Y.05eboe6PJSVn5uj7jRi_-CalOotF0T7iBWbBoduT35XgtNil0sknAAr89w~45fd546ea5b8a221565092e99a3f484e

Analyst Recommendations on Amicus Therapeutics, Inc.

JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating	Mar. 18	MT
Morgan Stanley Upgrades Amicus Therapeutics to Overweight From Equalweight, Raises Price Target to $20 From $15	Dec. 19	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	Nov. 09	MT
Morgan Stanley Trims Amicus Therapeutics' Price Target to $14 From $15, Keeps Equalweight Rating	23-10-10	MT
UBS Ups Price Target on Amicus Therapeutics to $20 From $19, Maintains Buy Rating	23-09-29	MT
JPMorgan Raises Price Target on Amicus Therapeutics to $19 From $17, Maintains Overweight Rating	23-09-29	MT
UBS Adjusts Amicus Therapeutics Price Target to $19 From $17, Maintains Buy Rating	23-08-09	MT
BofA Securities Adjusts Price Target on Amicus Therapeutics to $17 From $16, Maintains Buy Rating	23-03-28	MT
Goldman Sachs Adjusts Amicus Therapeutics' Price Target to $11 From $10, Keeps Neutral Rating	23-03-02	MT
UBS Adjusts Amicus Therapeutics Price Target to $17 From $15, Maintains Buy Rating	23-03-02	MT
BTIG Adjusts Price Target on Amicus Therapeutics to $16 From $14, Maintains Buy Rating	23-01-18	MT
Morgan Stanley Adjusts Price Target on Amicus Therapeutics to $15 From $14, Maintains Equalweight Rating	22-11-08	MT
Berenberg Bank Adjusts Amicus Therapeutics Price Target to $12 From $11 on Improved Confidence in AT-GAA, Maintains Hold Rating	22-11-01	MT
Morgan Stanley Initiates Amicus Therapeutics at Equalweight Rating With $14 Price Target	22-09-09	MT
Goldman Sachs Reinstates Amicus Therapeutics at Neutral With $11 Price Target	22-04-13	MT
Berenberg Bank Adjusts Amicus Therapeutics' Price Target to $12 From $14, Maintain Hold Rating	22-02-25	MT
SVB Leerink Upgrades Amicus Therapeutics to Outperform From Market Perform; Price Target is $16	22-01-14	MT
Cantor Fitzgerald Adjusts Amicus Therapeutics' Price Target to $15 from $16, Keeps Overweight Rating	22-01-13	MT
Stifel Lifts Amicus Therapeutics to Buy From Hold, Price Target to $16 From $12	21-11-15	MT
ANALYSTS' OPINIONS OF THE DAY : Admiral, Dollar Tree, EasyJet, Netflix, Planet Fitness...	21-11-15
AMICUS THERAPEUTICS : SVB Leerink Adjusts Amicus Therapeutics PT to $12 from $13, Maintains Market Perform Rating	21-09-30	MT
AMICUS THERAPEUTICS : JPMorgan Upgrades Amicus Therapeutics to Overweight From Neutral, Price Target at $16	21-09-30	MT
AMICUS THERAPEUTICS : Chardan Suspends Coverage on Akero Therapeutics at Neutral Rating With $12.50 Price Target	21-08-02	MT
AMICUS THERAPEUTICS : Needham Starts Amicus Therapeutics at Hold	21-05-27	MT
AMICUS THERAPEUTICS : UBS Initiates Coverage on Amicus Therapeutics With Buy Rating, $16 Price Target	21-05-21	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.54 USD

Average target price

18.78 USD

Spread / Average Target

+78.16%

High Price Target

22 USD

Spread / Highest target

+108.73%

Low Price Target

14 USD

Spread / Lowest Target

+32.83%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Amicus Therapeutics, Inc.

JPMorgan Chase
Morgan Stanley
UBS
BofA Securities
Goldman Sachs
BTIG
Berenberg Bank
SVB Leerink
Cantor Fitzgerald
Stifel Nicolaus
Chardan
Needham & Co.
J.P. Morgan Chase

Ratings for Amicus Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar